By combining long-standing expertise with new research solutions, Charles River advances drug discovery for treatments of respiratory diseases. Our validated rodent models provide rapid, cost-effective methods for evaluating the potential efficacy of novel anti-inflammatory and bronchodilator agents targeting chronic obstructive pulmonary disease (COPD), lung fibrosis and asthma conditions.

Webinar Replay

I need to...